Skip to main content
Alliance Equity Research
AER Insights
All insights
Biotechnology & Healthcare

SELLAS Reports a Survival Benefit in AML as Its Cancer Vaccine Approaches FDA Review

SELLAS Life Sciences reported that its investigational cancer vaccine met the overall-survival endpoint in a Phase 3 trial of patients with acute myeloid leukemia who had reached a second or later remission and could not undergo a donor stem cell transplant. Median survival was 24.0 months with galinpepimut-S versus 14.7 months with investigator-selected care. The result provides a basis for a planned FDA discussion, while detailed control-arm, safety and secondary-endpoint data remain important to interpretation. SELLAS ended September with $134.7 million in cash after substantial warrant exercises.

7 min read
Unlabeled vaccine vial in a laboratory with an illustrative blood-cell background.

SELLAS Life Sciences has reported a survival benefit for its investigational cancer vaccine in a Phase 3 trial of people with acute myeloid leukemia (AML) who reached a second or later remission and could not undergo a donor stem cell transplant. Median overall survival was 24.0 months for patients assigned galinpepimut-S, or GPS, versus 14.7 months for those assigned investigator-selected care.

The REGAL readout met its primary endpoint after the prespecified 80 deaths. It gives SELLAS a randomized survival result for a narrowly defined group with limited treatment options. The next assessment depends on the full analysis, including what patients received in the control arm, and an FDA discussion about whether the data support an application.

A vaccine given after remission

AML is a blood and bone marrow cancer in which abnormal immature cells can crowd out healthy blood-cell production. Patients who relapse after initial treatment may receive further therapy to bring the disease back into remission. Even after a remission, residual leukemia can lead to another relapse. A donor, or allogeneic, stem cell transplant can be an option for some patients, but the REGAL population consisted of people who were ineligible for or unable to undergo one.

GPS is an investigational immunotherapeutic vaccine licensed from Memorial Sloan Kettering Cancer Center. It contains four peptides derived from WT1, a protein expressed by many AML cells, and is designed to stimulate immune cells against WT1-expressing cancer. The intended role is maintenance after remission, when the aim is to prolong the period of disease control and survival. It is not being tested in REGAL as the treatment that first induces remission.

The trial enrolled patients in a second or later complete remission, or a second or later complete remission with insufficient platelet recovery, after salvage treatment. Those requirements define a smaller group than all people living with AML. The National Cancer Institute’s SEER program estimates 22,720 new U.S. AML cases in 2026, but that incidence figure cannot be used as the eligible market for GPS: patients must reach the relevant later remission, be unable to undergo transplant and meet any eventual approved-label criteria.

What the survival result shows

REGAL randomized 126 patients, in a 1:1 ratio, to GPS alone or the investigator’s choice of best available treatment. The primary endpoint was overall survival measured from study entry. The trial was open-label, meaning patients and treating teams knew which treatment had been assigned.

REGAL measureResult
Randomized population126 patients
Median overall survival, GPS24.0 months
Median overall survival, investigator-selected care14.7 months
Hazard ratio for death0.59
Two-sided p-value0.035
Prespecified event threshold80 deaths

Source: SELLAS’s November 17 topline release.

The difference between the reported medians was 9.3 months. The hazard ratio of 0.59 corresponds to a 41% lower relative rate of death over the study’s observed period, based on the trial’s analysis. It does not mean that every treated patient lived 9.3 months longer, or that the probability of death fell by exactly 41% for each patient.

Overall survival is a direct clinical outcome. The open-label design still makes the control-arm details important because investigators could select observation, a hypomethylating agent, venetoclax and/or low-dose cytarabine. The topline release does not say how many patients received each choice, or provide the survival confidence interval. Treatment mix, subsequent therapies and the detailed survival analysis will help clinicians and regulators judge how the comparison applies in practice.

SELLAS says prognostic stratification factors were balanced between groups. It also says few patients proceeded to stem cell transplantation and that they were equally distributed between arms. The release does not disclose the exact numbers, and detailed analyses of secondary outcomes, including leukemia-free survival and measurable residual disease, are still underway.

Safety and the path to an application

SELLAS described treatment-related adverse events as predominantly mild to moderate, most commonly injection-site reactions, and reported no new safety signals. The topline announcement does not provide a complete adverse-event table, serious-event rates or discontinuations by group. Those data will be needed to evaluate the burden of repeated treatment alongside the survival result.

The company plans to meet the FDA and prepare a biologics license application for GPS in the first half of 2027. That is a company target, not an accepted filing date or approval decision. SELLAS also intends to present additional analyses at a scientific meeting and submit them for peer-reviewed publication.

The FDA discussion is consequential because the evidence comes from one randomized study in a relatively small population, with investigator-selected treatments in the comparison arm. The primary endpoint was met, but the agency must evaluate the full dataset, manufacturing information and proposed indication. An accepted application and a commercial launch would be separate milestones.

If approved for a population resembling REGAL, GPS would enter a treatment pathway involving hematologists, patients recovering from salvage therapy, and insurers evaluating maintenance care. Its practical reach would depend on identifying patients at that specific point in treatment, the final label and reimbursement. The topline result does not establish a price, duration of use in routine practice or the number of eligible patients.

Cash improved through warrant exercises

SELLAS had $134.7 million in cash and equivalents at September 30, 2026, compared with $71.8 million at December 31, 2025. Management said in the quarterly filing that cash was expected to fund its current planned operations for at least 12 months from issuance of the statements. That estimate predates the readout and depends on the company’s planned spending; it is not a complete launch budget.

For the nine months ended September 30, operations used $22.4 million of cash, compared with $23.5 million in the comparable 2025 period. The $28.1 million net loss included $3.7 million of noncash stock compensation and $0.5 million of noncash lease expense. Working-capital movements added approximately $1.5 million to cash, principally an increase in accrued expenses, partly offset by lower payables and other movements.

Financing supplied $85.3 million, almost entirely the $85.1 million received when holders exercised warrants and pre-funded warrants. After the operating outflow, cash and restricted cash increased by $62.9 million. The increase therefore reflects financing proceeds rather than product sales. Common shares outstanding rose from 153.1 million at December 31 to 203.5 million at September 30, an increase of approximately 32.9%; warrant exercises were the main contributor. These are changes over the period, not a calculation of dilution from a single transaction.

Third-quarter research and development expense rose to $7.0 million from $4.2 million a year earlier, while general and administrative expense increased to $4.3 million from $2.9 million. The net loss widened to $10.1 million from $6.8 million, partly offset by higher interest income. Spending can change as SELLAS completes regulatory work and considers commercialization.

Other programs and rights

SELLAS is also developing tambiciclib, or SLS009, a CDK9 inhibitor, in AML. In its November 12 update, the company said 40 patients had been enrolled in an ongoing Phase 2 study in newly diagnosed patients, with preliminary topline data expected in the fourth quarter of 2026. That is a separate program and patient setting from GPS maintenance in REGAL.

Commercial rights also vary by territory. SELLAS licensed GPS rights for mainland China, Hong Kong, Macau and Taiwan to 3D Medicines. The filing says an arbitrator dismissed SELLAS’s claims in a dispute concerning, among other matters, development and milestone payments. Potential future partner payments are conditional and are not included in September cash.

The REGAL result moves GPS from an anticipated event to a reported survival finding in a defined later-remission population. The most useful next disclosure is the complete survival and safety dataset, especially control-arm treatment mix and subsequent therapies. Alongside the FDA’s response, it will determine how directly the 24.0-month result can support a filing and a future maintenance-treatment proposition.

This material is provided for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.

Companies Discussed

About AER Insights

Alliance Equity Research publishes timely insights on company-specific developments, industry trends, capital markets activity, and emerging investment themes across global public markets, with a particular focus on undercovered companies, sectors, and developments that often receive limited attention from mainstream financial research. Our analysis focuses on the financial, strategic, and valuation implications behind the headlines, using company disclosures, filings, market data, and sector context to help investors understand what matters, why it matters, and what to watch next.

Get AER Insights by Email

Receive new AER Insights and research updates in your inbox.

Subscribe
Glass capsule on a laboratory surface against an abstract neural network.Biotechnology & Healthcare

Helus Pharma’s Depression Trial Succeeds as Safety and Funding Questions Move Forward

Helus Pharma’s HLP003 met the primary endpoint in its first pivotal depression trial, producing a 7.6-point advantage over placebo on a symptom scale at six weeks. Patients remained on their existing antidepressants, and the benefit persisted at the study’s 12-week assessment. The results strengthen the case for an intermittent add-on treatment, although the nature of three treatment-related serious adverse events remains undisclosed. Quarterly filings show $171.1 million in cash at September 30 and continued clinical spending ahead of a second pivotal readout expected in late 2027.

Alliance Equity ResearchNovember 16, 20268 min read
Read article
Conceptual image of an unbranded medicine vial and blood glucose meter.Biotechnology & Healthcare

Amylyx’s Detailed Avexitide Results Bring a Rare Post-Surgery Condition Closer to Treatment

Amylyx has released detailed Phase 3 results for avexitide, an experimental daily injection for recurrent low blood sugar after gastric bypass. In 78 adults receiving dietary management, the treatment reduced the rate of specified hypoglycemic events over 16 weeks versus placebo. The company plans to seek U.S. approval by year-end and prepare for a possible 2027 launch. The study provides a clearer picture of the potential benefit, while diagnosis, insurance access, the approved patient population and sustained treatment will determine the commercial opportunity.

Alliance Equity ResearchNovember 15, 20266 min read
Read article
Conceptual aerial view of an open-pit mine with terraced earth and a winding haul road.Mining & Critical Minerals

Atalaya Adds Two Spanish Copper Projects as Its Growth Pipeline Competes for Capital

Atalaya Mining has acquired the former Tharsis and La Zarza mines in southern Spain for €125 million, adding large copper-bearing resources to a portfolio already led by its operating Riotinto complex and the proposed Touro development. The purchase follows a quarter of record EBITDA, helped by higher copper prices and increased sales. Although Atalaya paid €75 million upfront from cash, another €50 million is due within a year. The value of the expansion will depend on permitting, processing economics and how the new assets fit alongside existing investment priorities.

Alliance Equity ResearchNovember 13, 20267 min read
Read article
Offshore wind turbines in a line across the sea under a cloudy sky.Energy

RWE and KKR Share Capital Commitments as £12 Billion Wind Projects Advance

RWE and KKR have completed their partnership and secured financing for two British offshore wind farms requiring approximately £12 billion of investment. Each partner will own half of the projects, while RWE leads construction and delivery. Long-term power contracts provide greater revenue visibility, and project-level financing will help support development through expected commissioning in 2030. For investors, the transaction shares RWE’s capital commitments but leaves important details undisclosed, including the partners’ individual contributions. Construction costs, timing and electricity generation will determine how much value the projects ultimately deliver.

Alliance Equity ResearchNovember 11, 20266 min read
Read article
View all insights

About Alliance Equity Research

Alliance Equity Research publishes independent and company-sponsored equity research on undercovered, emerging, and high-potential public companies globally. Our analyst-built, model-backed research combines fundamental business analysis, financial forecasting, and valuation.

Email: info@alliancekp.com · Website: https://allianceequityresearch.com

For detailed company research, financial models, or coverage inquiries, contact our research team.

Research commentary for informational purposes. This document does not constitute personalized investment advice or a Buy, Hold, or Sell recommendation. For important disclosures, including information about research sponsorship and potential conflicts of interest, visit allianceequityresearch.com/disclosures.